MoneyWorks4Me

Senores Pharmaceutic - Quaterly Results

15 May 2025 Evaluate
The Revenue for the quarter ended  March 2025 of Rs. 118.60 millions grew by 11.78 % from Rs. 106.10 millions.The Total Profit for the quarter ended March 2025 of Rs. 20.10 millions grew from Rs.-33.30 millionsOperating Profit reported a sharp decline to 65.20 millions from 70.50 millions in the corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202503 202403 % Var 202503 202403 % Var 202503 202403 % Var
Sales 118.60 106.10 11.78 385.40 340.10 13.32 385.40 340.10 13.32
Other Income 92.50 51.70 78.92 219.90 68.40 221.49 219.90 68.40 221.49
PBIDT 65.20 70.50 -7.52 147.10 67.80 116.96 147.10 67.80 116.96
Interest 23.50 7.30 221.92 65.20 27.10 140.59 65.20 27.10 140.59
PBDT 41.70 63.20 -34.02 81.90 40.70 101.23 81.90 40.70 101.23
Depreciation 12.70 6.60 92.42 30.80 20.40 50.98 30.80 20.40 50.98
PBT 29.00 56.60 -48.76 51.10 20.30 151.72 51.10 20.30 151.72
TAX 8.90 89.90 -90.10 14.20 12.20 16.39 14.20 12.20 16.39
Deferred Tax 4.00 82.50 -95.15 -0.30 -1.40 -78.57 -0.30 -1.40 -78.57
PAT 20.10 -33.30 -160.36 36.90 8.10 355.56 36.90 8.10 355.56
Equity 460.50 305.10 50.93 460.40 305.10 50.90 460.40 305.10 50.90
PBIDTM(%) 54.97 66.45 -17.26 38.17 19.94 91.46 38.17 19.94 91.46
Peers
Company Name CMP
Sun Pharma. Inds. 1864.00
Dr. Reddys Labs. 1140.80
Cipla 1380.00
Lupin 2075.00
Zydus Lifesciences 1118.00
View more..